Maternal cholestasis during pregnancy programs metabolic disease in offspring by Papacleovoulou, Georgia et al.
Research article
3172 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 7   July 2013
Maternal cholestasis during pregnancy 
programs metabolic disease in offspring
Georgia Papacleovoulou,1,2 Shadi Abu-Hayyeh,1,2 Evanthia Nikolopoulou,1 Oscar Briz,3  
Bryn M. Owen,4 Vanya Nikolova,1,2 Caroline Ovadia,1 Xiao Huang,5,6 Marja Vaarasmaki,7  
Marc Baumann,6,8 Eugene Jansen,9 Christiane Albrecht,5,6 Marjo-Riitta Jarvelin,10,11,12  
Jose J.G. Marin,3 A.S. Knisely,13 and Catherine Williamson1,2
1Institute of Reproductive and Developmental Biology, Hammersmith Hospital, Imperial College London, London, United Kingdom.  
2Division of Women’s Health, Women’s Health Academic Centre, King’s College London, London, United Kingdom.  
3Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM), IBSAL, CIBERehd, University of Salamanca, Salamanca, Spain.  
4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 5Institute of Biochemistry and Molecular Medicine,  
6Swiss National Center of Competence in Research, NCCR TransCure, University of Bern, Bern, Switzerland.  
7Institute of Clinical Medicine/Obstetrics and Gynaecology, University of Oulu, Oulu, Finland. 8Department of Obstetrics and Gynecology,  
University Hospital, University of Bern, Bern, Switzerland. 9National Institute for Public Health and the Environment, Bilthoven, the Netherlands.  
10Department of Epidemiology and Biostatistics, MRC Health Protection Agency, Centre for Environment and Health, School of Public Health,  
Imperial College London, London, United Kingdom. 11Institute of Health Sciences and Biocenter Oulu, University of Oulu, Oulu, Finland.  
12Department of Children, Young People and Families, National Institute for Health and Welfare, Oulu, Finland.  
13Institute of Liver Studies, King’s College Hospital, London, United Kingdom.
The intrauterine environment is a major contributor to increased rates of metabolic disease in adults. Intra-
hepatic cholestasis of pregnancy (ICP) is a liver disease of pregnancy that affects 0.5%–2% of pregnant women 
and is characterized by increased bile acid levels in the maternal serum. The influence of ICP on the metabolic 
health of offspring is unknown. We analyzed the Northern Finland birth cohort 1985–1986 database and 
found that 16-year-old children of mothers with ICP had altered lipid profiles. Males had increased BMI, and 
females exhibited increased waist and hip girth compared with the offspring of uncomplicated pregnancies. 
We further investigated the effect of maternal cholestasis on the metabolism of adult offspring in the mouse. 
Females from cholestatic mothers developed a severe obese, diabetic phenotype with hepatosteatosis follow-
ing a Western diet, whereas matched mice not exposed to cholestasis in utero did not. Female littermates were 
susceptible to metabolic disease before dietary challenge. Human and mouse studies showed an accumulation 
of lipids in the fetoplacental unit and increased transplacental cholesterol transport in cholestatic pregnancy. 
We believe this is the first report showing that cholestatic pregnancy in the absence of altered maternal BMI 
or diabetes can program metabolic disease in the offspring.
Introduction
Over the last 2 decades, the prevalence of obesity and type 2 dia-
betes has grown, resulting in a worldwide epidemic. Sedentary 
lifestyle, unbalanced dietary habits, and genetic predisposition 
are major risk factors for cardiovascular-metabolic disease (1). 
However, these factors alone cannot explain the epidemic levels of 
metabolic disease. Human studies have shown that adult disease 
can originate in utero and during infancy. This led to the hypoth-
esis that the environment to which the parents are exposed can 
confer susceptibility to disease in the offspring in later life (2). For 
example, type 2 diabetes is more prevalent among people whose 
mothers experienced malnutrition during the Dutch famine (3), 
particularly in adults who were exposed to famine in utero after 
the first half of pregnancy, with the highest rates related to expo-
sure in the third trimester of pregnancy (4). Moreover, maternal 
obesity and gestational diabetes are associated with a high risk 
of metabolic syndrome in childhood (5, 6). Animal studies have 
shown that parental metabolic disorders can predispose the off-
spring to cardiovascular and metabolic disease in later life (7–9).
Intrahepatic cholestasis of pregnancy (ICP) is a metabolic dis-
ease of pregnancy with a complex etiology (10–12). Affected 
women have genetic variation in the biliary transporters (ABCB4 
and ABCB11) and nuclear receptors that influence bile acid (BA) 
homeostasis (10, 11, 13–16). The phenotype of ICP is likely to 
be caused by pathologically elevated levels of reproductive hor-
mone metabolites in genetically predisposed women (12, 17–19). 
Women with ICP present with pruritus and hepatobiliary injury 
with hypercholanemia (elevated serum BA levels) and dyslipi-
demia (20). Increased maternal BA levels in ICP are associated 
with adverse fetal outcomes, including spontaneous preterm 
labor, fetal hypoxia, and meconium-stained amniotic fluid (21). 
Fetal BA levels are elevated in cord blood in ICP pregnancies (22). 
We hypothesized that exposure of the fetus to elevated BA levels in 
utero in ICP increases susceptibility of the offspring to metabolic 
disorders in adulthood.
Results
ICP affects the metabolic profile of teenage offspring. To address 
whether ICP affects the metabolic health of the offspring, we 
analyzed the Northern Finland birth cohort 1985–1986 (NFBC 
1986) database. We identified 45 ICP cases (27 male and 18 
female offspring) that did not have any other known maternal 
liver/metabolic disease or other complications. No significant 
differences were observed in maternal BMI, placental size, or 
birth weight between normal and ICP cases. In both male and 
female ICP cases, the proportion of premature births (less than 
37 weeks of gestational age at birth) (23) was comparable to that 
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2013;123(7):3172–3181. doi:10.1172/JCI68927.
  Related Commentary, page 2786
Downloaded on June 25, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/68927
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
43
27
1 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 7   July 2013 3173
of the control pregnancies. Anthropometric and lipid analysis of 
the 16-year-old adolescents showed that males had significantly 
increased BMI and fasting insulin compared with the offspring 
of normal pregnancies. Females of the same age had significantly 
increased hip girth and waist girth as well as decreased fasting 
HDL cholesterol relative to females from normal pregnancies 
(Table 1). These data demonstrate that ICP impacts the subse-
quent metabolic health of the adolescent offspring.
Maternal hypercholanemia in mouse pregnancy results in metabolic dis-
ease of the offspring. To further investigate the influence of choles-
tatic pregnancy on subsequent metabolic disease of the offspring, 
we developed a murine model of maternal hypercholanemia by 
supplementing the diet of wild-type female mice with 0.5% cholic 
acid (CA). These mice had increased serum (24) and hepatic (17) 
BA levels. No differences in glucose tolerance or maternal body 
weight were observed relative to normal chow–fed (NC-fed) moth-
ers (Supplemental Figure 1, A and B; supplemental material avail-
able online with this article; doi:10.1172/JCI68927DS1). Moreover, 
there was no significant difference in litter size (albeit a small trend 
toward a reduced litter size in the CA-fed mice) or fetal body weight 
between NC-fed and CA-fed mothers (Supplemental Table 1). 
However, the CA-fed mice developed dyslipidemia, as indicated by 
increased lipid levels in the serum and liver (Supplemental Figure 
1, C and D). We assessed the metabolic phenotype of 18-week-old 
male and female offspring fed a lifelong NC or Western diet (WD) 
for 6 weeks. No alterations in body weight or glucose tolerance were 
observed among the offspring of NC-fed and CA-fed mothers until 
challenged with a WD. WD-fed female offspring of CA-fed mothers 
had an accelerated body weight gain after 2 weeks on the diet and 
developed impaired glucose tolerance as assessed 6 weeks after WD 
challenge (Figure 1, A and B). Additionally, these females were more 
dyslipidemic than the WD-fed females of NC-fed mothers, with 
increased serum cholesterol and LDL cholesterol, elevated levels 
of hepatic cholesterol, and FFAs (Table 2). Accordingly, increased 
vacuolization and lipid droplets (Figure 1C), as well as reduced 
AMPK-α and increased mTOR phosphorylation (Figure 1D) 
were observed in their livers, consistent with a hepatosteatotic phe-
notype (25, 26). These females did not respond to insulin stimula-
tion (Figure 1E), had enlarged pancreatic islets (Figure 1F), and had 
reduced hepatic insulin receptor-β (IR-β) expression (Figure 1G). 
Moreover, the WD-fed females from CA-fed mothers had signifi-
cantly increased liver and white adipose tissue (WAT) weight (Table 3), 
increased serum leptin levels and elevated inflammatory and met-
abolic markers (Supplemental Figure 2, A and B). Collectively, the 
WD-fed female offspring of CA-fed mothers developed a more 
severe obesogenic and diabetic phenotype than the WD-fed female 
offspring of NC-fed mothers. The hypercholanemic intrauterine 
environment also affected the metabolic phenotype of male off-
spring, but the effects were not as profound as in the female off-
spring. The male offspring of CA-fed mothers had significantly 
increased liver and WAT weight (Table 3) and showed a trend 
toward elevated hepatic cholesterol and triglycerides (TG) (Table 2).
Mouse cholestatic pregnancy results in an altered gene expression profile 
of liver and WAT in the WD-fed female offspring. To further examine the 
obesogenic and diabetic phenotype of the WD-fed female offspring 
of CA-fed mothers, we performed a gene expression microarray anal-
ysis of their livers and WAT. Transcriptomic analysis of the livers of 
WD-fed female offspring from hypercholanemic mothers revealed 
531 altered genes (146 downregulated and 385 upregulated), 
whereas WAT analysis revealed changes in 1,460 genes (308 down-
regulated and 1,152 upregulated) compared with  the liver and WAT 
of WD-fed female offspring from normal mothers (data not shown). 
Ingenuity pathway analysis (IPA) of the transcriptomic changes pre-
dicted an upregulation of pathways involved in increased fatty acid 
(FA) synthesis and cleavage, neutrophil infiltration, cell movement 
and migration, and inflammatory response (Supplemental Tables 2 
and 3). Moreover, a comparison of gene expression profiles of WAT-
cultured primary adipocytes and snap-frozen WAT, both isolated 
from the offspring of CA-fed mothers, showed a similar gene expres-
sion profile. This provides in vitro evidence for an adipocyte-pro-
gramming effect (Supplemental Figure 2C).
Offspring from CA-fed mothers are predisposed to metabolic disease. The 
data presented here support the hypothesis that offspring exposed 
to hypercholanemia in utero are predisposed to metabolic disease. 
Therefore, we investigated the phenotype of NC-fed offspring that 
were exposed to increased BA in utero. In both NC-fed male and 
female offspring, there was a trend toward elevated hepatic TG 
levels (Table 2) as well increased adiposity (Table 3) when exposed 
to hypercholanemia in utero. In both NC-fed female and male 
offspring, hepatic FFAs were significantly increased when born 
from CA-fed mothers (Table 2). Light microscopy revealed mild 
hepatosteatosis in the NC-fed female offspring of CA-fed mothers, 
as demonstrated by an increase in glycogen stores and small lipid 
droplets compared with the female offspring of NC-fed mothers 
(Figure 2A). Serum proinflammatory cytokines, such as CRP and 
TNF-α, were increased, and antiinflammatory cytokines, such as 
IL-11, were decreased in the NC-fed female offspring of CA-fed 
mothers. The latter also had increased levels of adipocytokines 
that positively correlate with insulin resistance (Figure 2B). More-
Table 1
Anthropometric and fasting lipid values in the 16-year-old 
offspring of ICP pregnancies (NFBC 1986 database)
Parameter Control ICP
Male offspring 
Maternal BMI (kg/m2) 22.20 ± 0.05 22.19 ± 0.7
Placenta weight (g) 655.40 ± 2.25 677.60 ± 30.3
Birth weight (g) 3,600 ± 1.04 3,600 ± 113.8
Hip girth (cm) 91.6 ± 0.14 95.5 ± 2.44
Waist girth (cm) 75.6 ± 0.16 74.77 ± 4.31
BMI (kg/m2) 21.07 ± 0.06 23.63 ± 1.2A
Insulin (mU/l) 10.76 ± 0.13 23.60 ± 7.5A
Apolipoprotein B (mmol/l) 0.65 ± 0.003 0.69 ± 0.03
HDL chol (mmol/l) 1.29 ± 0.006 1.34 ± 0.08
LDL chol (mmol/l) 2.13 ± 0.01 2.30 ± 0.16
Female offspring 
Maternal BMI (kg/m2) 22.30 ± 0.05 22.50 ± 1.23
Placenta weight (g) 645 ± 2.26 649 ± 29.9
Birth weight (g) 3,500 ± 12.2 3,400 ± 104.9
Hip girth (cm) 92.9 ± 0.13 96.7 ± 1.4A
Waist girth (cm) 71.8 ± 0.15 77.5 ± 2.3A
BMI (kg/m2) 21.17 ± 0.05 22.44 ± 0.7
Insulin (mU/l) 10.64 ± 0.11 10.08 ± 0.8
Apolipoprotein B (mmol/l) 0.68 ± 0.16 0.71 ± 0.03
HDL chol (mmol/l) 1.49 ± 0.05 1.36 ± 0.04A
LDL chol (mmol/l) 2.30 ± 0.01 2.36 ± 0.11
Males: control n = 4,034; ICP n = 27. Females: control n = 3,774; ICP  
n = 18. Values represent the mean ± SEM; AP ≤ 0.05. All measurements 
were adjusted for maternal BMI, parity, and gestational age at birth.
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Figure 1
Metabolic phenotype of 18-week-old female offspring. (A) Body weight from the day of weaning to 18 weeks of age; n = 8 animals per group. 
Dashed line: time of initiation of the WD. (B) Glucose tolerance test; n = 8 animals per group. (C) Representative image of PAS- (upper panel) 
and toluidine blue–stained (lower panel) livers; n = 6 animals per group. Original magnification, ×20 and ×5 (insets). (D) Immunoblotting against 
hepatic AMPK and mTOR in pooled samples from 6 animals per group. (E) Insulin tolerance test and serum insulin measurements; n = 6 animals 
per group. (F) Representative pancreatic H&E-stained sections; n = 6 animals per group. Original magnification, ×20 and ×5 (insets). (G) Immuno-
blotting for hepatic IR-β in pooled protein samples from 6 animals per group. *P ≤ 0.05 for differences in offspring fed a different diet; #P ≤ 0.05 for 
differences in offspring exposed to a different intrauterine environment. NC NC, NC-fed offspring from NC-fed mothers; NC WD, WD-fed offspring 
from NC-fed mothers; CA NC, NC-fed offspring from CA-fed mothers; CA WD, WD-fed offspring from CA-fed mothers.
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over, an unsupervised transcriptomic assessment of livers from 
NC-fed female offspring of CA-fed mothers demonstrated differ-
ential alterations in 985 genes. Of these changes, 668 were down-
regulated and 317 were upregulated compared with livers from 
NC-fed mothers (Figure 2C). IPA predicted an increased occur-
rence of inflammatory, immunological, cardiovascular, and met-
abolic disorders (Figure 2D), with upregulation of gene networks 
associated with NFKB and VEGF signaling (Supplemental Figure 
3). Collectively, these data illustrate increased inflammation in 
females that were exposed to a hypercholanemic intrauterine envi-
ronment, thereby predisposing them to metabolic disease that is 
unmasked when challenged with a WD.
Cholestatic pregnancy is associated with altered metabolic homeostasis in 
the fetoplacental unit. Metabolic disease in the offspring can be pro-
grammed in utero through alterations in the structure or function 
of organs at the fetomaternal interface, e.g., the placenta (27). To 
test the possibility of programming effects due to changes in feto-
maternal tissue structure and function, we investigated the met-
abolic phenotype on gestational day 18. We showed that fetuses 
from CA-fed mothers had a cholestatic profile as well as increased 
hepatic cholesterol and TG (Supplemental Table 4). Moreover, 
placentas from cholestatic mothers had elevated cholesterol and 
cholesteryl esters, increased mRNA levels of lipid storage–related 
genes, such as Adrp (Plin2) and Acat-2 (Figure 3, A and B), and pro-
found steatotic vacuolization in the cytotrophoblasts (Figure 3C). 
These data suggest that maternal cholestasis affects lipid bio-
synthesis and transport in the fetoplacental unit. In support 
of this, we found increased de novo 
hepatic FAs and cholesterol biosyn-
thesis in the fetuses of CA-fed moth-
ers (Supplemental Table 4). Injection 
of pregnant mice with 14C-cholesterol 
between days 12 and 17 of pregnancy, 
when active cholesterol transport 
from the mother to the fetus occurs 
(28), established increased 14C-cho-
lesterol in the placenta and fetal 
serum of hypercholanemic mice 
(Figure 3, D and E). These data are 
consistent with our observations in 
human pregnancies. We screened 
8 ICP placentas and demonstrated 
increased cholesterol and FFA levels 
(Figure 3F). Moreover, we performed 
apol ipoprote in  A1–dependent 
(APOA1-dependent) cholesterol 
efflux assays in primary human cyto-
trophoblasts and found increased 
cholesterol eff lux in response to 
100 μM of taurocholic acid (TCA) 
(Figure 3G). This concurred with the 
elevated cholesterol and LDL cho-
lesterol levels as well an increased 
cholesterol/HDL ratio in the umbil-
ical cord serum of ICP patients 
(Figure 3H). Overall, these findings 
directly establish that increased levels 
of BA in cholestatic pregnancy poten-
tiate excessive lipid transport and 
lipogenesis in the fetoplacental unit.
Hypercholanemia in mouse pregnancy is associated with alterations in 
the epigenome of the offspring. We used the agouti viable yellow (Avy) 
mouse (29) to investigate whether increased BA levels during ges-
tation affect the epigenome of the offspring. BA feeding of female 
mice (a/a) during pregnancy affected the coat color of both Avy/a 
female and male offspring (Supplemental Figure 4, A and B). Pre-
cisely, females shifted toward the pseudoagouti brown (hypometh-
ylation of the Avy cryptic promoter), and males to the agouti yellow 
phenotype (hypermethylation of the Avy cryptic promoter). To con-
firm that coat color grouping was consistent with the methylation 
status of the Avy cryptic promoter, we pyrosequenced at least 4 
samples per phenotype and ascertained that coat color is correlated 
with methylation status (Supplemental Figure 4C and refs. 30, 31).
Discussion
ICP is the most common liver-specific disease of pregnancy that 
affects up to 2% of pregnant women in different populations and 
is associated with maternal hypercholanemia and dyslipidemia 
(20, 22). It can have adverse outcomes for both the mother and 
the fetus. The majority of ICP research has focused on the etiology 
of the condition (12, 18, 22) and the causes of adverse pregnancy 
outcomes (32, 33), whereas there have been no reports of studies 
undertaken to explore the long-term effects of ICP on the health of 
the offspring. In the present study, we investigated the possibility 
of metabolic disease programming in offspring that were exposed 
to increased levels of BA in utero. To the best of our knowledge, 
we show for the first time, supported by several lines of evidence, 
Table 2
Serum and hepatic lipid profile of adult offspring
Mother and offspring Cholesterol LDL chol TG FFA 
 dietary regime
I. Serum (mmol/l)
Females
NC NC 1.76 ± 0.13 0.2 ± 0.07 0.39 ± 0.08 1.1 ± 0.16
NC WD 3.32 ± 0.18A  0.35 ± 0.03A  0.78 ± 0.19A  2.6 ± 0.79A
CA NC 1.75 ± 0.10 0.2 ± 0.03 0.39 ± 0.03 0.85 ± 0.06
CA WD 3.97 ± 0.09B  0.42 ± 0.01A B 0.65 ± 0.11A  2.16 ± 0.08A
Males
NC NC 2.23 ± 0.12 1.29 ± 0.14 1.23 ± 0.29 1.57 ± 0.35
NC WD 5.65 ± 0.21A  4.29 ± 0.2A 1 ± 0.08 1.1 ± 0.09
CA NC 2.14 ± 0.17 1.35 ± 0.17 0.93 ± 0.11 0.99 ± 0.08
CA WD 5.7 ± 0.41A  4.22 ± 0.32A 0.95 ± 0.08 1.26 ± 0.19
II. Liver (μmol/mg protein)
Females
NC NC 0.012 ± 0.002 NA 0.25 ± 0.03 0.14 ± 0.03
NC WD 0.06 ± 0.01A NA 0.92 ± 0.11A 0.17 ± 0.05
CA NC 0.015 ± 0.003 NA 0.32 ± 0.12 0.25 ± 0.05B
CA WD 0.07 ± 0.008A,B NA 0.84 ± 0.13A 0.29 ± 0.06B
Males
NC NC 0.013 ± 0.003 NA 0.19 ± 0.03 0.1 ± 0.02
NC WD 0.074 ± 0.003A  NA 0.84 ± 0.11A 0.15 ± 0.03
CA NC 0.015 ± 0.01 NA 0.35 ± 0.12 0.25 ± 0.03B
CA WD 0.09 ± 0.01A NA 0.93 ± 0.12A 0.15 ± 0.03
NC NC, NC-fed offspring from NC-fed mothers; NC WD, WD-fed offspring from NC-fed mothers; CA NC, 
NC-fed offspring from CA-fed mothers; CA WD, WD-fed offspring from CA-fed mothers; n = 6 animals 
per group. AP ≤ 0.05 for differences in offspring fed a different diet; BP ≤ 0.05 for differences in offspring 
exposed to a different intrauterine environment. Values represent the mean ± SEM.
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that cholestatic pregnancy can program metabolic disease in the 
offspring. We performed both human and animal studies to estab-
lish, in vitro and in vivo, that maternal hypercholanemia affects 
the subsequent health of the offspring. Furthermore, we show that 
metabolic programming of the offspring originates in utero due to 
altered lipid homeosteotatic pathways in the fetoplacental unit, as 
a consequence of increased BA levels in the maternal bloodstream 
and the associated dyslipidemia.
Our initial investigation sought to determine whether ICP is 
likely to have an impact on human offspring. We interrogated the 
NFBC 1986 database and found that 16-year-old children of ICP 
mothers had altered lipid profiles. Also, males had increased BMI, 
and females had increased waist and hip girth. This phenotype 
is likely due to the direct result of ICP on the fetus, as pregnant 
women with diabetes and preeclampsia were excluded, and the 
data were adjusted to correct for the effects of maternal BMI, par-
ity, and gestational age at birth. Thus, we aimed to avoid the con-
founding effects of disorders known to program metabolic disease 
in the offspring (34–36). We also found levels of lipids in umbilical 
cord serum from ICP cases to be increased at term. We are not 
aware of any medical interventions before or at delivery that could 
result in a dyslipidemic phenotype, either in the offspring of ICP 
cases from the NFBC 1986 database, or in the ICP pregnancies 
from which umbilical cord serum was collected. In cases of labor 
induction, the most common methods used were prostaglandins 
or oxytocin administration. Collectively, these data suggest that 
no factors other than maternal hypercholanemia in ICP affected 
the metabolic phenotype of term and adolescent offspring.
To further investigate metabolic disease in the offspring from 
cholestatic pregnancy, we developed a murine metabolic program-
ming model of maternal hypercholanemia in which the offspring 
had increased susceptibility to metabolic syndrome. We established 
that maternal hypercholanemia affects the metabolic phenotype of 
the male and female offspring, with the female offspring develop-
ing a more severe obesogenic and diabetic phenotype that was fur-
ther unmasked by WD feeding. The female offspring from CA-fed 
mothers were characterized by increased body weight, impaired 
glucose tolerance, reduced insulin sensitivity, hepatosteatosis, and 
an increased inflammatory response in liver and WAT. Although 
WD-fed male offspring had a less severe phenotype, they did have 
substantially increased white fat deposition and some features of 
dyslipidemia. There are several potential explanations for the gen-
der discrepancies between female and male mouse and human 
offspring in response to a hypercholanemic intrauterine environ-
ment, including the relatively short duration of WD feeding, the 
adolescent nature of the NFBC 1986 offspring, and species-specific 
differences (37). However, the metabolic profiles of both males and 
females exposed to increased BA in utero, in both the mouse model 
and in humans with ICP, were associated with a preobese and predi-
abetic phenotype as well as altered morphometric and biochemical 
profiles. This demonstrates an increased susceptibility of the off-
spring to metabolic disease. We therefore conclude that maternal 
hypercholanemia in mice and humans has long-term implications 
for the health of their male and female offspring.
The phenotype of offspring exposed to CA in utero was con-
sistent with the metaflammation hypothesis, a proinflammatory 
state that is directly correlated with obesity and contributes to 
the development of insulin resistance and metabolic dysfunc-
tion (38–40). In support of this, female offspring from CA-fed 
mothers had a proinflammatory, predisease phenotype that had 
features of metabolic syndrome after a WD challenge. The accel-
erated weight gain was not associated with hyperphagia, as litter-
mates consumed equal amounts of food irrespective of the dietary 
regime they were exposed to prenatally and postnatally (data 
not shown). Moreover, hyperleptinemia was not present prior 
to dietary stress. It is plausible that the accelerated weight gain 
contributed to the impaired glucose tolerance, as this was noted 
6 weeks after commencement of the WD. These data reveal that 
a hypercholanemic in utero environment can increase the sensi-
tivity of the offspring to the aberrant effects of a WD challenge.
Unlike other metabolic diseases of pregnancy (41–43), no differ-
ences were observed in body birth weight or placental weight in 
ICP, indicating that neither of these factors is likely to be responsi-
ble for metabolic disease programming in the offspring. However, 
given that maternal dyslipidemia has been reported in ICP (20) 
and lipid parameters are raised in our cholestatic mouse model, it 
was plausible to hypothesize that hypercholanemia in pregnancy 
affects maternal-fetal nutrient/lipid availability and transfer. We 
showed, in vivo and in vitro, that hypercholanemia potentiates 
excessive cholesterol storage and transport in the fetoplacental 
unit, thereby altering fetal energy homeostasis. This is likely to 
continue postnatally, resulting in an altered metabolic phenotype 
in adult life, which can be unmasked when challenged by an envi-
ronmental insult such as a WD, giving rise to metabolic disease. 
This is consistent with the thrifty phenotype hypothesis, in which 
fetal adaptations to survive a poor intrauterine environment are 
preserved throughout life (44).
Although the precise mechanisms that cause the BA-mediated 
programming effect in the offspring are not known, we were able 
to use the Avy mouse model (29–31) to demonstrate that BA feed-
ing has an impact on the epigenome of the offspring. This is an 
important result, as it has been shown that in utero epigenetic 
alterations in the placenta and fetal blood can program metabolic 
disease in the offspring (45, 46). However, more detailed studies 
are required to investigate whether epigenetic mechanisms affect 
the lipidemic profile observed in the fetoplacental unit in response 
Table 3
Tissue weight (g) analysis of offspring
 Offspring diet
Maternal diet NC WD
Females
NC 0.97 ± 0.03 1.2 ± 0.1A Liver
CA 0.95 ± 0.04 1.6 ± 0.13A,B
NC 0.26 ± 0.02 0.83 ± 0.11A  Subcutaneous WAT
CA 0.35 ± 0.05 1.38 ± 0.18A,B 
NC 0.36 ± 0.04 1.1 ± 0.23A Gonadal WAT
CA 0.5 ± 0.12 2.1 ± 0.23A,B 
Males
NC 1.19 ± 0.05 2.3 ± 0.37A Liver
CA 1.34 ± 0.1 2.65 ± 0.09A,B 
NC 0.34 ± 0.02 1.0 ± 0.08A  Subcutaneous WAT
CA 0.42 ± 0.02 1.19 ± 0.06A 
NC 0.7 ± 0.02 2.01 ± 0.08A Gonadal WAT
CA 0.9 ± 0.02 2.5 ± 0.06A,B 
n = 8 animals per group. AP ≤ 0.05 for differences in offspring fed a dif-
ferent diet; BP ≤ 0.05 for differences in offspring exposed to a different 
intrauterine environment. Values represent the mean ± SEM.
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to a hypercholanemic environment. It is likely that the program-
ming phenotype reported here shares components of other mod-
els of metabolic programming, specifically those precipitated by 
maternal metabolic disease, such as maternal obesity (47, 48).
These models of metabolic programming can be used to eval-
uate therapeutic or lifestyle interventions to prevent metabolic 
syndrome and hepatosteatosis in young adults. Ursodeoxycholic 
acid (UDCA) is used to treat ICP, as it has been clinically shown 
to ameliorate the symptoms and improve the BA profiles of 
affected women and neonates (49–51). In addition to treating 
the maternal symptoms of ICP, UDCA administration to an 
affected mother with ICP may improve the future metabolic 
health of her children. The maternal and fetal serum BA levels 
achieved with CA feeding of mice (24) are similar to the levels 
reported in ICP (22). Given that ICP affects up to 2% of women, 
it is feasible that cholestasis-related development of subsequent 
metabolic disease is a relatively common occurrence in human 
pregnancy. Furthermore, asymptomatic hypercholanemia of 
pregnancy (serum BA levels above the reference range, but no 
additional clinical features to suggest a diagnosis of ICP) is 
approximately 3 times more prevalent than ICP (52), implying 
that metabolic disease of the offspring due to intrauterine expo-
sure to increased BA is a frequent phenomenon.
To our knowledge, this is the first direct evidence showing that 
cholestatic pregnancy can program metabolic disease in the off-
spring. We show altered metabolic phenotypes in 16-year-old 
teenagers from ICP mothers who are not diabetic or lean/obese. 
Determining the metabolic profiles of these offspring at an older 
age is warranted, and it will give further insight into the predis-
position to cardiometabolic disease in the offspring as a result of 
maternal cholestasis. Moreover, we show, using a mouse model 
and an in vitro human model, that maternal hypercholanemia 
can alter the fetoplacental phenotype, which confers susceptibil-
ity of the offspring to metabolic disease.
Methods
Human population study
The NFBC 1986 (53) human database was analyzed for ICP cases. We eval-
uated mothers and 16-year-old children from 7,808 control (4,034 male 
Figure 2
Female offspring from a cholestatic pregnancy are predisposed to metabolic disease. (A) Representative images of PAS- (upper panel) and 
toluidine blue–stained (lower panel) livers in NC-fed female offspring; n = 6 animals per group. Original magnification, ×20 and ×5 (insets). (B) 
Alterations in serum adipocytokines in CA NC female offspring as assessed in 6 serum samples per animal group. (C) Unsupervised hierarchical 
clustering of differentially expressed hepatic genes in CA NC compared with NC NC female offspring; n = 4 animals per group. (D) IPA of differ-
entially expressed genes from C. Threshold denotes cutoff for statistical significance. NC NC and CA NC are as defined in Figure 1.
Downloaded on June 25, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/68927
research article
3178 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 7   July 2013
and 3,774 female) pregnancies and 45 ICP (27 male and 18 female) preg-
nancies. UDCA was not used to treat these women, and no medical deliv-
ery interventions were reported. In cases of labor induction, oxytocin or 
prostaglandins were the main methods used. We excluded pregnancies in 
which disease or a complication other than ICP was diagnosed (e.g., viral 
hepatitis, obesity, diabetes, or preeclampsia). All parameters analyzed were 
adjusted for maternal BMI, gestational age at birth, and parity.
Human samples
Placental tissue samples from 8 control pregnancies and 8 ICP pregnancies 
(serum BA levels ≥40 μM) (21) were collected and snap frozen in liquid 
nitrogen. Placental extracts were prepared in 0.125 M potassium phos-
phate buffer (pH 7.4) containing 1 mM EDTA and 0.1% Triton X-100 (all 
from Sigma-Aldrich) and were subjected to basic lipid measurements (cho-
lesterol, FFAs, and TG) using an LX20 multiplex autoanalyzer (Beckman 
Figure 3
Metabolic phenotype of the fetoplacental unit in cholestatic pregnancy. (A) Lipid measurements of mouse placenta; n = 6 animals per group. (B) 
Gene expression levels of Adrp and Acat2 mRNA in mouse placenta; n = 6 animals per group. (C) Representative murine toluidine blue–stained 
placental sections; n = 6 animals per group. Original magnification, ×20 and ×5 (insets). (D and E) Distribution of 14C-cholesterol in placenta and fetal 
serum/tissues; n = 8 for NC-fed mothers and n = 5 for CA-fed mothers. *P ≤ 0.05. (F) Lipid measurements of human placenta; n = 8 animals per group. 
(G) APOA1-mediated cholesterol efflux in human cytotrophoblasts. Representative graph of 1 experiment performed in triplicate. Error bars represent 
SD. *P < 0.05 versus control; #P < 0.05 versus taurocholic acid (TCA) and control. (H) Lipid measurements in umbilical cord serum. ICP cases, n = 19; 
control cases, n = 9. *P < 0.05 versus control. Chol, cholesterol; LDL-CHOL, LDL cholesterol; HDL-CHOL, HDL cholesterol (as defined in Table 1).
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Coulter). All values were normalized to total protein content measured 
with a BCA kit (Thermo Scientific). Human umbilical cord serum samples 
from term ICPs (serum BA levels ≥40 μM) and control pregnancies (18 and 
10 cases, respectively) were collected for basic lipid measurements (choles-
terol, LDL cholesterol, HDL cholesterol, TG).
Animal handling
Female C57BL6 mice between 10 and 12 weeks of age (Harlan, UK) that 
had already delivered their first litter were used. Mice were fed an NC diet 
(RM3 control diet) or an RM3 diet supplemented with 0.5% CA (Lillico) 
for 1 week before mating and throughout gestation. Pregnant mothers 
were either sacrificed on day 18 of pregnancy (day 1 of pregnancy was 
considered the day of plug identification) after a 4-hour fast, following 
which fetal and maternal tissues and serum were collected, or they were 
allowed to deliver. Mothers were switched to an NC diet upon delivery, 
and the litter size was reduced to 4 pups (when possible, 2 males and 
2 females). No differences in the female/male ratio were observed in the 
offspring of NC-fed or CA-fed mice (data not shown). The offspring 
were weaned after 3 weeks’ lactation. When they reached 12 weeks of age, 
1 female and 1 male offspring from each litter were fed a WD (Lillico) for 
6 weeks, whereas their littermates were kept on an NC diet. At 18 weeks 
of age, the offspring were sacrificed for further analysis after a 4-hour 
fast. Body weight and food intake (in grams) were monitored weekly from 
weaning to termination. Fasting consistently took place from 8:30 am 
to 12:30 pm. Two independent cohorts of animals were set up (8 litters 
from NC-fed and 8 litters from CA-fed mothers, with different mothers 
for each cohort). Data from 1 animal cohort are presented for simplicity, 
but both gave consistent results.
For the epigenomic studies, the Avy mouse strain was used. This was a 
gift from Mark Christian (Institute of Reproductive and Developmental 
Biology, Imperial College London, London, United Kingdom). Females 
(10 to 12 weeks of age, a/a) were fed with an NC or CA diet for 1 week 
before mating with an Avy/a male (30). CA feeding continued throughout 
gestation and switched to an NC diet upon delivery. Seventy Avy/a off-
spring per maternal dietary regime were collected and separated into males 
and females. Male and female offspring were grouped according to their 
coat color as previously described (30). Liver, kidney, and brain, represent-
ing all the embryonic germ layers, were collected (31).
Glucose and insulin tolerance tests
Glucose and insulin tolerance tests (GTT and ITT, respectively) were 
performed after a 6-hour fast (from 8:30 am to 2:30 pm). For pregnancy 
experiments, mothers were assessed on day 18 of pregnancy, and for off-
spring studies, mice fed an NC diet or a WD were assessed 48 hours before 
euthanasia. Different littermates were assessed for GTT and ITT. Glucose 
(1 g/kg of body weight; Sigma-Aldrich) or insulin (humalin; 0.75 U/kg of 
body weight; Eli Lilly) was injected intraperitoneally. Blood glucose levels 
were monitored for 2 hours (from 2:30 to 4:30 pm) at the indicated time 
points after injection with a Freestyle Lite glucose sensor (Abbott Diabetes 
Care). Tail blood was also collected for insulin measurements.
Biochemical analysis
Serum and tissue biochemical parameters (cholesterol, LDL choles-
terol, HDL cholesterol, TG, and FFAs) were measured using an LX20 
autoanalyzer (Beckman Coulter). Liver and placenta were extracted in a 
0.125 M potassium phosphate buffer and normalized to the total protein 
content as described above. Free cholesterol in tissue extracts and insu-
lin and leptin in serum were measured using commercially available kits 
(Alpha Laboratories, for free cholesterol; Mercodia, for insulin; and Milli-
pore, for leptin). Adipocytokines were assessed in pooled serum samples 
from 5 animals per group with a commercial array kit (R&D Systems), and 
several of these adipokines (e.g., leptin and adiponectin) were reassessed 
with ELISA kits (Millipore) to validate the data.
Histologic and morphometric analysis
Upon euthanasia, tissues were weighed before snap freezing or fixation. 
PAS and/or H&E staining were performed in liver, placenta, and pancreas 
(≥6 per dietary regime). Placentas (6 from NC-fed mothers and 6 from 
CA-fed mothers) and livers from female offspring (6 per dietary regime) 
were osmicated with tetroxide, followed by toluidine blue staining. A histo-
pathologist blinded to the group’s identity assessed the samples.
Western immunoblotting
Equal concentrations of protein samples from the same group of animals 
(6 per group) were pooled, and 30 μg of protein was size fractionated with 
SDS-PAGE and transferred onto PVDF membranes. Membranes were probed 
for phospho-AMPK-α (T172; Cell Signaling Technology, 2535), AMPK-α 
(Cell Signaling Technology, 2532), phospho-mTOR (Ser2448; Cell Signaling 
Technology, 2971), mTOR (Cell Signaling Technology, 2972), and insulin 
receptor-β (sc-711; Santa Cruz Biotechnology). GAPDH (MAB374; Millipore) 
and α-tubulin (T9026; Sigma-Aldrich) were used as loading controls.
Quantitative real-time PCR
Total RNA was extracted from livers of at least 6 animals per group with 
the RNeasy mini kit (QIAGEN). RNA (1 μg) was reverse transcribed 
into cDNA with the Superscript II kit (Invitrogen). Real-Time PCR was 
performed with the SYBR green (Sigma-Aldrich) reagent. The primer 
sequences (Sigma-Aldrich) are given in Supplemental Table 5.
Transcriptomic analysis
Total RNA (4 samples per group) was extracted, and 100 ng RNA with RNA 
integrity number (RIN) 7.5 was reverse transcribed with a transplex whole 
transcriptome amplification kit (Sigma-Aldrich). Transcriptomic analysis 
was performed using Roche NimbleGen mouse gene expression arrays, and 
data were analyzed with Partek and IPA software.
Bisulfite conversion and pyrosequencing
Identification of DNA methylation levels at individual CpG sites within the 
Avy cryptic promoter (IAP LTR retrotransposon) was performed (30, 31). 
Genomic DNA from liver, brain, and kidney of 3-week-old Avy/a male and 
female offspring from NC- or CA-fed mothers was extracted (QIAGEN), 
and bisulfite was modified using the EZ DNA Methylation-Gold kit (Zymo 
Research). Target DNA was amplified with Invitrogen Platinum Taq poly-
merase, followed by pyrosequencing (54) using previously published prim-
ers (31). At least 4 samples per phenotype were pyrosequenced. No differ-
ences in CpG methylation were observed in the 3 different tissue extracts 
from the same animal (data not shown).
Primary adipocyte culture and differentiation
Primary adipocytes were isolated and differentiated as described (55). 
Pooled fat tissue dissected from 4 females fed a WD (4 from NC-fed 
mothers, 4 from CA-fed mothers) was used. Equal numbers of cells were 
seeded in duplicate and were grown to confluence. RNA was extracted, 
in parallel, from undifferentiated cells and from cells that were differ-
entiated for 1 week in DMEM/10% FBS plus insulin, dexamethasone, 
transferrin, and T3 (Sigma-Aldrich). Quantitative PCR (qPCR) was per-
formed for Ap2 to confirm differentiation. Differentiated cells were then 
assessed for genes of interest (Ctgf, Col4a1, Nos). Target gene expression 
levels were normalized to Ap2 mRNA levels. The primers used are listed 
in Supplemental Table 5.
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Study approval
Human studies. The NFBC 1986 (http://kelo.oulu.fi/NFBC/) was approved 
by the Ethics Committee of the University of Oulu and Northern Osthro-
bothnia Hospital District. The review board of the University of Bern 
approved the ethics of the study of human placental samples. Analysis 
of umbilical cord samples was approved by the Hammersmith Hospi-
tal Research Ethics Committee (97/5197 and 08/H0707/21). Written 
informed consent was obtained from all participants.
Animal studies. All experimental procedures were approved by the Eth-
ical Committee for Animal Welfare at Imperial College London, and 
all animal studies were performed in accordance with the UK Animals 
(Scientific Procedures) Act of 1986 and the guidelines from the Biolog-
ical Sciences Unit at Imperial College London. Cholesterol transport 
studies were approved by the University of Salamanca Ethical Commit-
tee for the Use of Laboratory Animals.
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Cholesterol transport assays in mice
Pregnant NC-fed (n = 8) or CA-fed mice (n = 5) (Harlan) were injected 
into the tail vein with 2 μCi 14C-cholesterol per day (specific activity 
45 mCi/mmol; PerkinElmer) dissolved in 0.5 ml of saline solution (150 mM 
NaCl) containing 2% ethanol. 14C-cholesterol was administered for 6 days 
until day 17 of pregnancy. On day 18 of pregnancy, mice were fasted for 
4 hours before collecting serum and tissue samples. Total cholesterol con-
centrations in maternal serum were determined enzymatically to calculate 
the corrected specific radioactivity of 14C-cholesterol, which was used to 
determine cholesterol levels in the maternal and fetal serum and tissues 
by radioactivity measurement. Tissues were homogenized in saline solu-
tion and then chemically digested with soluene and H2O2, mixed with iso-
propanol and scintillation cocktail, and radioactivity was measured in an 
LS-1800 Beckman scintillation counter (Beckman Coulter) (56).
Cholesterol efflux studies in primary human cytotrophoblasts
Cholesterol efflux was performed in primary human cytotrophoblasts 
isolated from term human placentas as previously described (57). Cells 
were seeded and grown overnight and then treated with 1 μCi/ml of 
3H-cholesterol (PerkinElmer) for 24 hours. Efflux was induced with 
0.1 μM of TO901317 (LXR agonist; Sigma-Aldrich) in the presence or 
absence of 100 μM taurocholic acid (TCA; Sigma-Aldrich) for 24 hours 
followed by treatment with 10 μM of APOA1 (Sigma-Aldrich) for 8 hours. 
Medium was then collected and cells were washed 3 times in PBS sup-
plemented with 1 mg/ml of BSA and then dissolved in 0.1M of NaOH. 
Subsequently, 3H-cholesterol in media and cells were counted in liquid 
scintillation fluid using a Tri-Carb 2100TR Liquid Scintillation Counter 
(Packard). Cholesterol efflux was calculated with the following equation: 
cholesterol efflux % = cpm in supernatant / (cpm [cells + supernatant]). 
Efflux assays were set up in 4 independent cytotrophoblast cultures, and 
triple replicates were performed within each culture.
Statistics
For the NFBC 1986 database analysis, we used Stata version 11.2 (Stata-
Corp). All measurements analyzed were adjusted for confounding factors 
such as maternal BMI, gestational age at birth, and parity. For human 
sample comparisons, nonparametric, 2-tailed Mann-Whitney U testing 
was used. For animal studies, single comparisons were performed with 
unpaired 2-tailed t testing, whereas multiple measures of ANOVA and 
Newman-Keuls post-hoc testing were run for multiple comparisons. The 
significance cutoff was set at P ≤ 0.05.
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